- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01672008
NOX-100 for Preventing Hypotension During Hemodialysis
A Phase IIa Study of Safety and Efficacy of NOX-100 for Preventing Hypotension in Patients During Hemodialysis Sessions
Study Overview
Detailed Description
This is a 2-stage, prospective, randomized, double-blind, multi-dose, placebo-controlled, cross-over, phase IIa study to evaluate the safety, tolerability and efficacy profiles of NOX-100 to reduce the number of intradialytic hypotension episodes. At single-blind stage I, the eligible subject will receive a 1-week run-in period followed by a 1-week NOX-100 treatment in a dose of 0.4mg/kg/hr. To evaluate the clearance of NOX-100, plasma levels of NOX-100 at the end of the 1st dialysis and prior to the 2nd dialysis will be measured. An interim analysis will be undertaken after the completion of first stage. The following process should be conducted only if the plasma level of NOX-100 decreases by 90% or more in these patients and all safety data have been reviewed by the medical monitor.
At double blind stage II, patients will be randomized to one of the following treatment sequences in a 1:1 ratio.
- Sequence A: NOX-100 treatment phase followed by Placebo treatment phase
- Sequence B: Placebo treatment phase followed by NOX-100 treatment phase
After a 1-week placebo, the subjects will receive the two 4-week treatment (sequence A or sequence B)which are separated by 1-week wash-out. In the NOX-100 treatment phase, subjects will subsequently receive NOX-100 in doses of 1.2, 2.5, 5, and 10 mg/kg/hr at the first three dialysis sessions over each week. In the placebo treatment phase, subjects will receive comparative placebo for four weeks. For the first 20 subjects, the treatment dose could be escalated only after the individual safety data have been reviewed by an unblinded medical monitor.
To confirm if there is hepatic metabolism of NOX-100 between dialysis sessions, a pre-dialysis plasma level will be tested at the 2nd dialysis of Week 2, 5, 7 and 10 in the second stage.
In both stages, the blood pressure will be measured pre-HD, every 30 minutes during HD and post-HD for monitoring the hypotension episode. For safety assessment, all AE(s), SAE(s) and any signs/symptoms during HD will be recorded. The safety of study drug will be followed until 4 weeks after last treatment.
A Data and Safety Monitoring Board (DSMB) will be established prior to start of the trial and the DSMB meeting will be hold every 6~12 months during study period. Both medical monitor and DSMB will be responsible for safeguarding the interests of trial participants.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan, 83301
- Kaohsiung Chang Gung Memorial Hospital
-
Keelung, Taiwan, 20401
- Keelung Chang Gung Memorial Hospital
-
New Taipei City, Taiwan, 22056
- Far Eastern Memorial Hospital
-
New Taipei City, Taiwan, 23142
- Buddhist TzuChi General Hospital, Taipei Branch
-
Taichung, Taiwan, 40447
- China Medical University Hospital
-
Taipei, Taiwan, 11168
- Shin Kong Wu Ho-Su Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or non-pregnant, non-lactating females 20-80 years of age
- Patients who are hemodialysis dependent with a history of end-stage renal disease (ESRD) for at least 3 months and need at least three HD sessions per week
- History of intradialytic hypotension defined by at least 4 episodes with a fall in SBP of > 20 mmHg within 30 days prior to signing the ICF. At least two of the episodes must have caused symptoms requiring an intervention
- No change in anti-hypertensive regimen for at least one month prior to enrollment/randomization
- Be willing to sign the Informed Consent Form
Exclusion Criteria:
- Subjects with adequate laboratory results at screening
- Subjects with major psychiatric illness
- Subjects with history of arrhythmia or severe congestive heart failure (New York Heart Association (NYHA) Class III and IV) within past 6 months, or those with hypoxic myocardium confirmed by EKG
- Subjects with history of cirrhosis
- Subjects with active infection disease defined as current treatment with anti-infection agent(s)
- Subjects who need to receive nitrate and nitrite medication(s) (such as nitroglycerin, isosorbide mononitrate, and isosorbide dinitrate) for regular treatment
- Subjects who need to receive unstable dose of midodrine, etilefrine or amezinium treatment within 7 days prior to receive the study treatment.
- More than 14 drinks of alcohol per week
- Use of any investigational drug or participation in any drug study within 30 days prior to enrollment/randomization
- Any clinical condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk to participate in the study or confounds the ability to interpret data from the study as judged by the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NOX-100/Placebo
After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio. Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase |
|
Experimental: Placebo/NOX-100
After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio. Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of hypotension episode requiring intervention
Time Frame: 10 weeks
|
Number reduction of symptomatic hypotension requiring intervention during HD with NOX-100 treatment.
|
10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
systolic blood pressure (SBP)
Time Frame: 10 weeks
|
Change in systolic blood pressure
|
10 weeks
|
Onset of symptoms of hypotension during HD
Time Frame: 10 weeks
|
Time to onset of symptoms of hypotension during HD
|
10 weeks
|
The need for treatment intervention to raise BP.
Time Frame: 10 weeks
|
Time to conduct a treatment intervention to raise BP
|
10 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Monte Lai, Ph.D., Medinox, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NOX-100-ORIENT201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypotension
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Edwards LifesciencesCompletedHypotension | Intraoperative Hypotension | Postoperative HypotensionNetherlands
-
James J. Peters Veterans Affairs Medical CenterCompleted
-
Attikon HospitalRecruitingHypotension During Surgery | Prevention of HypotensionGreece
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingHypotension Drug-Induced | Hypotension During Surgery
-
Universitätsklinikum Hamburg-EppendorfCompletedBlood Pressure | Postinduction Hypotension | Perioperative HypotensionGermany
-
University of ParmaUnknownHypotension During Dialysis | Dialysis HypotensionItaly
-
Peking Union Medical College HospitalRecruitingPost-induction Hypotension | Postprandial HypotensionChina
-
Mazovia Regional Hospital in SiedlceRecruitingAnesthesia | Hypotension on Induction | Perioperative Injury | Perioperative HypotensionPoland
-
Acibadem UniversityCompletedHypotension | Intraoperative Hypotension | Post-induction Hypotension | Post Anesthesia RecoveryTurkey
-
Seoul National University HospitalCompletedOrthostatic; Hypotension, NeurogenicKorea, Republic of
Clinical Trials on NOX-100
-
TME Pharma AGProfil Institut für Stoffwechselforschung GmbHCompletedType 2 Diabetes MellitusGermany
-
TME Pharma AGCompletedType 2 Diabetes Mellitus | Systemic Lupus Erythematosus | Chronic Inflammatory Diseases
-
Chinese University of Hong KongCompleted
-
TME Pharma AGCompletedRenal ImpairmentHungary, Moldova, Republic of
-
TME Pharma AGCompletedType 2 Diabetes Mellitus | AlbuminuriaPoland, Germany, Romania, Hungary, Czech Republic
-
TME Pharma AGGerman Federal Ministry of Education and ResearchCompleted
-
TME Pharma AGCompletedAnemia | End Stage Renal DiseaseUnited Kingdom, Germany, Italy
-
TME Pharma AGCompletedHematopoietic Stem Cell TransplantationGermany
-
Children's Hospital of PhiladelphiaAmerican Academy of Sleep MedicineRecruitingSleep Apnea Syndromes | Sleep Apnea, Obstructive | Sleep Disorder | Sleep DisturbanceUnited States
-
TME Pharma AGMerck Sharp & Dohme LLCCompletedMetastatic Colorectal Cancer | Metastatic Pancreatic CancerGermany